Fig. 5: Increased NO reduces PCa tumor burden and pro-tumorigenic signatures.
From: S-nitrosylation of CSF1 receptor increases the efficacy of CSF1R blockage against prostate cancer
A Representative bright-field, H and E and immunofluorescent images and DAB chromogenic substrate showing expression of CD206 in 22Rv1 derived organoids. Scale bar 400 μm. B Graph showing %DAB intensity for CD206 expression. Data are ±SEM. Scale bar 400 μm. C Mean change of tumor volume (±SEM; versus tumor volume at treatment start) in C5BL6 mice treated as indicated in the flow diagram. Vehicle (n = 5), S-nitrosoglutathione, GSNO (n = 5). Animal weight plots throughout the experiment from Day 1 to Day 28. Tumor weight plotted as Mean ± SEM (n = 5) measured at the end of the experiment. D Representative immunofluorescent images for tumor sections for mice treated with vehicle and GSNO and stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue) and Cysteine sulfinic acid (red) (n = 3). E Graphs showing the percentage of various immune cell populations in tumor grafts representing percentage of iNOS + /MHCII + (M1-macrophages), CD206+, F4/80+ (M2-macrophages) and CD11b+ myeloid cells. Also, the cytotoxic T cell population (CD8+), EM-CD8+ (CD44+ CD62L−), MEM− CD8+ (CD44+ CD62L+), and naive CD8+ are represented in GSNO tumors treated as indicated and analyzed by flow cytometry (Mean ± SEM). Statistical analysis by Student’s t-test. ***P < 0.001; **P < 0.01; *P < 0.05. ns = not significant.
